39. C.F. Price, D. Tyssen, S. Sonza, A. Davie, S. Evans, G.R. Lewis et al., SPL7013 Gel
(VivaGel
®
) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 6(9), e24095 (2011)
40. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J.W. Weener et al.,
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary
studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control
Release. 65, 133–148 (2000)
41. K. Jain, P. Kesharwani, U. Gupta, N.K. Jain, Dendrimer toxicity: let’s meet the challenge. Int.
J. Pharm. 394, 122–142 (2010)
42. V. Biricová, A. Lázničková, M. Lázníček, M. Polášek, P. Hermann, Radio-labeling of
PAMAM dendrimers conjugated to a pyridine-N-oxide DOTA analog with
111
In: optimization of reaction conditions and biodistribution. J. Pharm. Biomed. Anal. 56(3), 505–512
(2011)
43. L.M. Kaminskas, B.J. Boyd, P. Karellas, G.Y. Krippner, R. Lessene, B. Kelly, C.J. Porter,
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of
PEGylated poly l-lysine dendrimers. Mol. Pharm. 5(3), 449–463 (2008)
44. J.W. Seo, H. Baek, L.M. Mahakian, J. Kusunose, J. Hamzah, E. Ruoslahti et al.,
64
Cu-labeled
LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug. Chem. 25(2),
231–239 (2014)
45. J. Hamzah, V.R. Kotamraju, J.W. Seo, L. Agemy, V. Fogal, L.M. Mahakian et al., Specific
penetration and accumulation of a homing peptide within atherosclerotic plaques of
apolipo-protein E-deficient mice. Proc. Natl. Acad. Sci. U S A. 108(17), 7154–7159 (2011)
46. B.P. Gray, S. Li, K.C. Brown, From phage display to nanoparticle delivery: functionalizing
liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug.
Chem. 24(1), 85–96 (2013)
47. L. Kovacs, M. Tassano, M. Cabrera, C.B. Zamboni, M. Fernández, R.M. Anjos et al.,
Development of
177
Lu-DOTA-dendrimer and determination of its effect on metal and ion
levels in tumor tissue. Cancer Biother. Radiopharm. 30(10), 405–409 (2015)
48. L. Zhao, J. Zhu, Y. Cheng, Z. Xiong, Y. Tang, L. Guo et al., Chlorotoxin-conjugated
multifunctional dendrimers labeled with radionuclide
131
I for single photon emission
computed tomography imaging and radiotherapy of gliomas. ACS Appl. Mater. Interfaces. 7
(35), 19798–19808 (2015)
49. G. Yang, N. Sadeg, H. Belhadj-Tahar, New potential in situ anticancer agent derived from
[
188
Re]rhenium nitro-imidazole ligand loaded 5th generation poly-L-lysine dendrimer for
treatment of transplanted human liver carcinoma in nude mice. Drug Des. 6, 144 (2017)
50. C.P. Reis, R.J. Neufeld, A.J. Ribeiro, F. Veiga, Nanoencapsulation I. Methods for preparation
of drug-loaded polymeric nanoparticles. Nanomedicine 2, 8 (2006)
51. I.H. Park, J.H. Sohn, S.B. Kim, K.S. Lee, J.S. Chung, S.H. Lee et al., An open-label,
randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric
micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for
recurrent or metastatic HER2-negative breast cancer. Cancer Res. Treat. 49(3), 569–577
(2017)
52. J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Cancer nanomedicine: progress,
challenges and opportunities. Nat. Rev. Cancer 17(1), 20–37 (2017)
53. D.E. Owens 3rd, N.A. Peppas, Opsonization, biodistribution, and pharmaco-kinetics of
polymeric nanoparticles. Int. J. Pharm. 307(1), 93–102 (2006)
54. E.D. Pressly, R. Rossin, A. Hagooly, K. Fukukawa, B.W. Messmore, M.J. Welch et al.,
Structural effects on the biodistribution and positron emission tomography (PET) imaging of
well-defined
64
Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers.
Biomacromol 8(10), 3126–3134 (2007)
55. R. Toita, Y. Kanai, H. Watabe, K. Nakao, S. Yamamoto, J. Hatazawa et al., Biodistribution of
125
I-labeled polymeric vaccine carriers after subcutaneous injection. Bioorg. Med. Chem. 21
(17), 5310–5315 (2013)
122
K. W. Kang and M. G. Song
(VivaGel
®
) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 6(9), e24095 (2011)
40. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J.W. Weener et al.,
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary
studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control
Release. 65, 133–148 (2000)
41. K. Jain, P. Kesharwani, U. Gupta, N.K. Jain, Dendrimer toxicity: let’s meet the challenge. Int.
J. Pharm. 394, 122–142 (2010)
42. V. Biricová, A. Lázničková, M. Lázníček, M. Polášek, P. Hermann, Radio-labeling of
PAMAM dendrimers conjugated to a pyridine-N-oxide DOTA analog with
111
In: optimization of reaction conditions and biodistribution. J. Pharm. Biomed. Anal. 56(3), 505–512
(2011)
43. L.M. Kaminskas, B.J. Boyd, P. Karellas, G.Y. Krippner, R. Lessene, B. Kelly, C.J. Porter,
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of
PEGylated poly l-lysine dendrimers. Mol. Pharm. 5(3), 449–463 (2008)
44. J.W. Seo, H. Baek, L.M. Mahakian, J. Kusunose, J. Hamzah, E. Ruoslahti et al.,
64
Cu-labeled
LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque. Bioconjug. Chem. 25(2),
231–239 (2014)
45. J. Hamzah, V.R. Kotamraju, J.W. Seo, L. Agemy, V. Fogal, L.M. Mahakian et al., Specific
penetration and accumulation of a homing peptide within atherosclerotic plaques of
apolipo-protein E-deficient mice. Proc. Natl. Acad. Sci. U S A. 108(17), 7154–7159 (2011)
46. B.P. Gray, S. Li, K.C. Brown, From phage display to nanoparticle delivery: functionalizing
liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug.
Chem. 24(1), 85–96 (2013)
47. L. Kovacs, M. Tassano, M. Cabrera, C.B. Zamboni, M. Fernández, R.M. Anjos et al.,
Development of
177
Lu-DOTA-dendrimer and determination of its effect on metal and ion
levels in tumor tissue. Cancer Biother. Radiopharm. 30(10), 405–409 (2015)
48. L. Zhao, J. Zhu, Y. Cheng, Z. Xiong, Y. Tang, L. Guo et al., Chlorotoxin-conjugated
multifunctional dendrimers labeled with radionuclide
131
I for single photon emission
computed tomography imaging and radiotherapy of gliomas. ACS Appl. Mater. Interfaces. 7
(35), 19798–19808 (2015)
49. G. Yang, N. Sadeg, H. Belhadj-Tahar, New potential in situ anticancer agent derived from
[
188
Re]rhenium nitro-imidazole ligand loaded 5th generation poly-L-lysine dendrimer for
treatment of transplanted human liver carcinoma in nude mice. Drug Des. 6, 144 (2017)
50. C.P. Reis, R.J. Neufeld, A.J. Ribeiro, F. Veiga, Nanoencapsulation I. Methods for preparation
of drug-loaded polymeric nanoparticles. Nanomedicine 2, 8 (2006)
51. I.H. Park, J.H. Sohn, S.B. Kim, K.S. Lee, J.S. Chung, S.H. Lee et al., An open-label,
randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric
micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for
recurrent or metastatic HER2-negative breast cancer. Cancer Res. Treat. 49(3), 569–577
(2017)
52. J. Shi, P.W. Kantoff, R. Wooster, O.C. Farokhzad, Cancer nanomedicine: progress,
challenges and opportunities. Nat. Rev. Cancer 17(1), 20–37 (2017)
53. D.E. Owens 3rd, N.A. Peppas, Opsonization, biodistribution, and pharmaco-kinetics of
polymeric nanoparticles. Int. J. Pharm. 307(1), 93–102 (2006)
54. E.D. Pressly, R. Rossin, A. Hagooly, K. Fukukawa, B.W. Messmore, M.J. Welch et al.,
Structural effects on the biodistribution and positron emission tomography (PET) imaging of
well-defined
64
Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers.
Biomacromol 8(10), 3126–3134 (2007)
55. R. Toita, Y. Kanai, H. Watabe, K. Nakao, S. Yamamoto, J. Hatazawa et al., Biodistribution of
125
I-labeled polymeric vaccine carriers after subcutaneous injection. Bioorg. Med. Chem. 21
(17), 5310–5315 (2013)
122
K. W. Kang and M. G. Song